Want to join the conversation?
During 1Q16, $MYL's largest contributing segment Generics third party net sales increased 17% to $1.93Bil compared to the prior year period, helped by higher sales in North America, Europe and Rest of World. Specialty segment third party net sales rose 17% during 1Q16 helped by higher net sales of the EpiPen Auto-Injector due to higher volumes.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.